US biotech Moderna (Nasdaq: MRNA) has announced preliminary neutralizing antibody data against the Omicron variant following the company’s booster candidates at 50µg and 100µg dose levels.
The currently authorized 50µg booster of mRNA-1273, or Spikevax, increased neutralizing antibody levels against Omicron approximately 37-fold compared to pre-boost levels, while a 100µg dose of mRNA-1273 increased neutralizing antibody levels approximately 83-fold compared to pre-boost levels.
"Moderna will continue to rapidly advance an Omicron-specific booster candidate into clinical testing"Stéphane Bancel, chief executive of Moderna, said: “The dramatic increase in COVID-19 cases from the Omicron variant is concerning to all. However, these data showing that the currently authorized Moderna COVID-19 booster can boost neutralizing antibody levels 37-fold higher than pre-boost levels are reassuring.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze